Clinical trials: Lymphoid
Acute Lymphoblastic Leukemia
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred).
- Trial name
- NCT00440726
- Testing
- Bortezomib, Dexamethasone, PEG-asparaginase
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 31 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.
- Trial name
- NCT03913949
- Testing
- APG-2575
- Where
- 5 sites in China
- Volunteers
- 74 people
- Sponsor
- Ascentage Pharma Group Inc.
Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute
Phase I, Dose Escalation Study of Decitabine
Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML).
- Conditions
- Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute, Hematopoetic Myelodysplasia
- Trial name
- NCT02264873
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
Recent advances in allogeneic hematopoietic cell transplantation (allo-SCT) have led to reduce intensity preparative regimens that are non-myeloablative and reduce the toxicities associated with the transplant.
- Trial name
- TLI-ATG (NCT01566656)
- Testing
- total lymphoid irradiation and anti-thymocyte globulin
- Where
- 4 sites in France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus
Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
The overall survival of acute lymphoblastic leukemia (ALL) and lymphoma in children and adolescents is above 90%. The survival rate has increased significantly during the last decades as a consequence of more intensive…
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Induced Diabetes Mellitus, Impaired Glucose Tolerance, Lymphoma
- Trial name
- NCT05873322
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Aarhus University Hospital
Lymphoblastic Lymphoma
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
- Trial name
- NCT00187122
- Testing
- Vincristine, Radiation Therapy, Daunomycin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed or Refractory B Cell Leukemia and Lymphoma
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
- Trial name
- NCT06834529
- Testing
- CAR2219-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Relapsed or Refractory Chronic Lymphocytic Leukemia
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT03739554
- Testing
- CYC065, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia
CLL is an incurable disease with conventional chemotherapy. In the absence of TP53 disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line treatment in those patients who attained a long…
- Trial name
- NCT03847727
- Testing
- BR as Maintenance
- Where
- Russia
- Volunteers
- 112 people
- Sponsor
- Pirogov Russian National Research Medical University
Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than…
- Trial name
- NCT01949129
- Testing
- VP16, TBI, Thiotepa
- Where
- 119 sites in Argentina, Australia and 29 more
- Volunteers
- 1,800 people
- Sponsor
- St. Anna Kinderkrebsforschung
Acute Lymphoblastic Leukemia, Acute Leukemia
Dependence Receptors and Leukemia
Acute leukaemias (AL) are the first cause of cancer in children, with a majority of B acute lymphoblastic leukemia (ALL). Some of the processes causing leukemogenesis are already identified and well characterized in some AL…
- Trial name
- NCT03278145
- Testing
- Genetic analyses
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Hematopoietic and Lymphoid System Neoplasm, Malignant Breast Neoplasm
Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms
This clinical trial evaluates the use of virtual reality (VR) goggles during chemotherapy infusion to reduce anxiety-related symptoms in patients with head and neck, thoracic, hematologic, and breast cancers.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Breast Neoplasm, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05793957
- Testing
- Questionnaire Administration, Telephone-Based Intervention, Virtual Technology Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
This phase II MATCH treatment trial identifies the effects of palbociclib in patients whose cancer has genetic changes called CCND1, 2, or 3 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439201
- Testing
- Palbociclib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies.
- Trial name
- NCT00038857
- Testing
- Megadose of CD34 Selected Progenitor Cells, Melphalan, Thiotepa
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors
Treatment of acute lymphoblastic leukemia achieves high cure rate, but is potentially neurotoxic. Long-term neurologic morbidity in survivors and its effect on function are inadequately studied.
- Trial name
- NCT00664131
- Testing
- Neurological Examination/Questionnaires
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Lymphocytic, Acute, Leukemia
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
This is a phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Acute Lymphoid Leukemia (ALL)
- Trial name
- NCT00313053
- Testing
- Human mAb 216, Vincristine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Clare Twist
Lymphoblastic Leukemia, Acute
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to investigate the efficacy and safety for treating adult ALL patients with the pediatric protocol.
- Trial name
- NCT00131053
- Testing
- Methotrexate, Prednisolone, Dexamethasone
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Japan Adult Leukemia Study Group
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
The investigators propose an early phase study defined as a phase I/II trial assessing safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) cells for participants with…
- Conditions
- Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- CLIC-01 (NCT03765177)
- Testing
- CLIC-1901
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Ottawa Hospital Research Institute
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
In cancer inpatient settings, intravenous (IV) opioids are frequently administered in a bolus fashion in order to obtain immediate pain relief.
- Trial name
- NCT04296305
- Testing
- Hydromorphone, Questionnaire Administration
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Malignancy, Non-Hodgkin Lymphoma
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy…
- Conditions
- B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT05294731
- Testing
- Tacabrutideg
- Where
- 29 sites in China
- Volunteers
- 146 people
- Sponsor
- BeOne Medicines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.